Significant Weight Loss Data from Olatorepatide Revealed at EASD 2026 Conference

Major Breakthrough in Weight Management: Olatorepatide's Phase III Results

The annual meeting of the European Association for the Study of Diabetes (EASD) took place in Milan, Italy, from September 28 to October 2, 2026. A significant highlight of this year's conference was the presentation of data from a phase III study regarding olatorepatide (HS-20094), a novel dual-action GLP-1/GIP receptor agonist developed by Hansoh Pharma.

During the session dedicated to 'Late-breaking Abstracts,' researchers showcased the results from the LIGHTEN trial, which assessed the weight management efficacy of olatorepatide in overweight or obese adults. The findings are remarkable, revealing an impressive average weight loss of 19.3% at the 48-week mark among participants receiving a 15 mg dose of olatorepatide without any observed plateau in the weight loss curve.

Study Design and Participant Details

The LIGHTEN study was a multicenter, randomized, double-blind, placebo-controlled trial involving 604 Chinese adults with overweight or obesity—defined as having a body mass index (BMI) of 28 kg/m² or greater, or a BMI between 24 and 28 kg/m² accompanied by weight-related comorbidities. Participants were randomly assigned to receive either 5 mg, 10 mg, or 15 mg of olatorepatide or a placebo via weekly subcutaneous injections for a duration of 48 weeks.

Approximately 90.1% of participants completed the study, demonstrating high adherence to the treatment regimen. The primary endpoints measured the percentage change in body weight from baseline after 48 weeks and the proportion of participants achieving a weight loss of at least 5%.

The results were striking, with average weight reductions of -12.5%, -17.5%, and -19.3% observed in the 5 mg, 10 mg, and 15 mg olatorepatide groups respectively, compared to only -2.7% in the placebo group. This highlighted the significant efficacy of olatorepatide, with all differences between groups being statistically significant (P<0.0001).

Achieving Weight Loss Goals

Additionally, when assessing the achievement of weight loss goals, the proportions of participants achieving specified thresholds for weight loss were as follows: 87.3%, 97.2%, and 95.2% for a weight loss of ≥5% in the respective treatment groups compared to 28.6% in the placebo group. For those achieving ≥10% and ≥15% weight loss, the rates were markedly higher in the olatorepatide groups, emphasizing its effectiveness compared to placebo.

Such consistent and significant reductions suggest that continued treatment could yield even more considerable results over a more extended period.

Positive Metabolic Effects

Olatorepatide also resulted in favorable changes in various metabolic parameters. Participants displayed improvements in blood pressure, lipid profiles, glycated hemoglobin (HbA1c), and other metabolic markers like insulin resistance and uric acid levels. This indicates that olatorepatide could offer comprehensive metabolic benefits alongside weight management.

Regarding safety, the overall safety profile of olatorepatide was comparable to that of existing GLP-1 receptor-based treatments. Notably, the incidence of gastrointestinal adverse effects—nausea (7.8%), vomiting (4.9%), diarrhea (16.9%), and constipation (5.1%)—was lower than that seen with other medications in this category, with no participants discontinuing treatment due to adverse events.

Conclusion and Future Outlook

As a dual-action GLP-1 and GIP receptor agonist, olatorepatide represents a novel approach to addressing the challenges of weight loss while ensuring tolerability. The LIGHTEN phase III trial confirms its significant efficacy in weight management, positioning it as a promising new treatment option.

Moreover, the EASD conference, recognized as one of the leading scientific gatherings focused on diabetes and metabolism research globally, afforded high recognition to olatorepatide's clinical data and its potential impact on the scientific community.

Olatorepatide, administered through a weekly subcutaneous injection, modulates critical metabolic pathways responsible for appetite regulation and energy balance. Additionally, ongoing clinical trials for the treatment of type 2 diabetes further demonstrate its expansive therapeutic role.

In June 2025, Hansoh Pharmaceutical secured a strategic collaboration with Regeneron, granting exclusive rights for international development and commercialization of olatorepatide. Furthermore, the application for marketing approval (NDA) has been submitted to China's National Medical Products Administration (NMPA), which is currently under review.

Hansoh Pharma emphasizes its commitment to innovation, with a focus on key therapeutic areas such as oncology, metabolism, and immunology, continuing to work towards enhancing quality of life globally.